Emmanuelle Waubant

46.3k total citations · 3 hit papers
228 papers, 21.0k citations indexed

About

Emmanuelle Waubant is a scholar working on Pathology and Forensic Medicine, Neurology and Molecular Biology. According to data from OpenAlex, Emmanuelle Waubant has authored 228 papers receiving a total of 21.0k indexed citations (citations by other indexed papers that have themselves been cited), including 170 papers in Pathology and Forensic Medicine, 60 papers in Neurology and 37 papers in Molecular Biology. Recurrent topics in Emmanuelle Waubant's work include Multiple Sclerosis Research Studies (163 papers), Peripheral Neuropathies and Disorders (44 papers) and Polyomavirus and related diseases (25 papers). Emmanuelle Waubant is often cited by papers focused on Multiple Sclerosis Research Studies (163 papers), Peripheral Neuropathies and Disorders (44 papers) and Polyomavirus and related diseases (25 papers). Emmanuelle Waubant collaborates with scholars based in United States, Canada and France. Emmanuelle Waubant's co-authors include Paul O’Connor, Brian G. Weinshenker, Kazuo Fujihara, Jerry S. Wolinsky, Fred Lublin, M. Clanet, Massimo Filippi, Michael Hutchinson, Xavier Montalbán and Ludwig Kappos and has published in prestigious journals such as New England Journal of Medicine, JAMA and SHILAP Revista de lepidopterología.

In The Last Decade

Emmanuelle Waubant

220 papers receiving 20.5k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria

2011 7.6k citations Emmanuelle Waubant, Jerry S. Wolinsky et al. Annals of Neurology profile →
B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis

2008 1.8k citations Emmanuelle Waubant, Douglas L. Arnold et al. profile →
Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double‐blind placebo‐controlled multicenter trial

2009 686 citations Emmanuelle Waubant et al. Annals of Neurology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Emmanuelle Waubant United States	57	15.3k	6.1k	4.1k	3.6k	3.3k	228	21.0k
Eva Havrdová Czechia	57	18.7k 1.2×	6.2k 1.0×	4.4k 1.1×	4.8k 1.3×	3.1k 0.9×	385	23.5k
Per Soelberg Sørensen Denmark	73	13.2k 0.9×	5.7k 0.9×	3.6k 0.9×	3.4k 0.9×	2.5k 0.8×	447	21.8k
Michael Hutchinson Ireland	54	13.9k 0.9×	6.6k 1.1×	3.4k 0.8×	3.6k 1.0×	2.5k 0.7×	295	21.8k
Jeffrey A. Cohen United States	69	13.2k 0.9×	5.6k 0.9×	2.6k 0.6×	3.2k 0.9×	4.1k 1.2×	314	22.7k
Paul O’Connor Canada	52	19.7k 1.3×	6.9k 1.1×	4.3k 1.1×	4.8k 1.3×	3.4k 1.0×	152	25.1k
Gavin Giovannoni United Kingdom	79	14.1k 0.9×	7.2k 1.2×	4.2k 1.0×	3.2k 0.9×	4.3k 1.3×	678	26.2k
Richard A. Rudick United States	71	16.0k 1.0×	5.5k 0.9×	2.9k 0.7×	4.1k 1.1×	3.2k 1.0×	214	21.7k
Bianca Weinstock‐Guttman United States	75	15.3k 1.0×	5.7k 0.9×	1.9k 0.5×	3.5k 1.0×	2.5k 0.7×	518	20.5k
Bernard M.J. Uitdehaag Netherlands	68	12.1k 0.8×	4.1k 0.7×	2.3k 0.6×	3.0k 0.8×	2.5k 0.8×	457	18.7k
Tanuja Chitnis United States	64	11.2k 0.7×	5.7k 0.9×	3.8k 0.9×	2.9k 0.8×	2.6k 0.8×	365	17.6k

Countries citing papers authored by Emmanuelle Waubant

Since Specialization

Citations

This map shows the geographic impact of Emmanuelle Waubant's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emmanuelle Waubant with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emmanuelle Waubant more than expected).

Fields of papers citing papers by Emmanuelle Waubant

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emmanuelle Waubant. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emmanuelle Waubant. The network helps show where Emmanuelle Waubant may publish in the future.

Co-authorship network of co-authors of Emmanuelle Waubant

This figure shows the co-authorship network connecting the top 25 collaborators of Emmanuelle Waubant. A scholar is included among the top collaborators of Emmanuelle Waubant based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emmanuelle Waubant. Emmanuelle Waubant is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cordano, Christian, Emmanuelle Waubant, & Bardia Nourbakhsh. (2024). The observation of seasonal variation of fatigue in multiple sclerosis depends on the measurement instrument. Multiple Sclerosis and Related Disorders. 94. 106252–106252. 1 indexed citations

George, Elizabeth, Jeffrey B. Russ, Mark D. Mamlouk, et al.. (2024). Clinical and Imaging Findings in Children with Myelin Oligodendrocyte Glycoprotein Antibody Associated Disease (MOGAD): From Presentation to Relapse. American Journal of Neuroradiology. 45(2). 229–235. 4 indexed citations

Zhu, Feng, Ali Mirza, Amit Bar‐Or, et al.. (2022). Stability of the gut microbiota in persons with paediatric-onset multiple sclerosis and related demyelinating diseases. Multiple Sclerosis Journal. 28(11). 1819–1824. 4 indexed citations

Krupp, Lauren, Brenda Banwell, Tanuja Chitnis, et al.. (2022). Effect of fingolimod on health-related quality of life in paediatric patients with multiple sclerosis: results from the phase 3 PARADIGMS Study. BMJ Neurology Open. 4(1). e000215–e000215. 8 indexed citations

Mandel, L., Ellen O’Donnell, Katia M. Canenguez, et al.. (2021). Family Perspectives on Clinical Research for Pediatric Multiple Sclerosis: Enhancing Equity. SHILAP Revista de lepidopterología. 8. 652548695–652548695.

Waldman, Amy, Leslie Benson, Amy M. Lavery, et al.. (2020). Interocular Difference in Retinal Nerve Fiber Layer Thickness Predicts Optic Neuritis in Pediatric-Onset Multiple Sclerosis. Journal of Neuro-Ophthalmology. 41(4). 469–475. 7 indexed citations

Chitnis, Tanuja, Brenda Banwell, Lauren Krupp, et al.. (2020). Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy in paediatric patients with multiple sclerosis: Results from the PARADIGMS study. Multiple Sclerosis Journal. 27(6). 922–932. 7 indexed citations

Krysko, Kristen M., et al.. (2019). A retrospective cohort study of plasma exchange in central nervous system demyelinating events in children. Multiple Sclerosis and Related Disorders. 35. 50–54. 20 indexed citations

Zipp, Frauke, Jiwon Oh, Yára Dadalti Fragoso, & Emmanuelle Waubant. (2019). Implementing the 2017 McDonald criteria for the diagnosis of multiple sclerosis. Nature Reviews Neurology. 15(8). 441–445. 18 indexed citations

10.

Waubant, Emmanuelle, et al.. (2018). Pediatric glial fibrillary acidic protein meningoencephalomyelitis: A case report and review of the literature. Multiple Sclerosis and Related Disorders. 29. 148–152. 14 indexed citations

11.

Nourbakhsh, Bardia, et al.. (2017). Treatment of fatigue with methylphenidate, modafinil and amantadine in multiple sclerosis (TRIUMPHANT-MS): Study design for a pragmatic, randomized, double-blind, crossover clinical trial. Contemporary Clinical Trials. 64. 67–76. 17 indexed citations

12.

Schlaeger, Regina, Nico Papinutto, Valentina Panara, et al.. (2014). Spinal cord gray matter atrophy correlates with multiple sclerosis disability. Annals of Neurology. 76(4). 568–580. 143 indexed citations

13.

Wilson, Leslie, Lixian Zhong, Elizabeth Crabtree, et al.. (2014). Patient centered decision making: Use of conjoint analysis to determine risk–benefit trade-offs for preference sensitive treatment choices. Journal of the Neurological Sciences. 344(1-2). 80–87. 64 indexed citations

14.

Chitnis, Tanuja, Marc Tardieu, Maria Pia Amato, et al.. (2013). International Pediatric MS Study Group Clinical Trials Summit. Neurology. 80(12). 1161–1168. 48 indexed citations

15.

Chitnis, Tanuja, Charles R.G. Guttmann, Alexander Musallam, et al.. (2013). Quantitative MRI analysis in children with multiple sclerosis: a multicenter feasibility pilot study. BMC Neurology. 13(1). 173–173. 5 indexed citations

16.

Hosseini, Hassan, Tomasz Mandat, Emmanuelle Waubant, et al.. (2011). Unilateral Thalamic Deep Brain Stimulation for Disabling Kinetic Tremor in Multiple Sclerosis. Neurosurgery. 70(1). 66–69. 24 indexed citations

17.

Chitnis, Tanuja, Lauren Krupp, E. Ann Yeh, et al.. (2011). Pediatric Multiple Sclerosis. Neurologic Clinics. 29(2). 481–505. 64 indexed citations

18.

Okuda, Darin T., Ellen M. Mowry, A. Beheshtian, et al.. (2008). Incidental MRI anomalies suggestive of multiple sclerosis. Neurology. 72(9). 800–805. 392 indexed citations

19.

Gajofatto, Alberto, et al.. (2008). Switching first-line disease-modifying therapy after failure: impact on the course of relapsing–remitting multiple sclerosis. Multiple Sclerosis Journal. 15(1). 50–58. 71 indexed citations

20.

Waubant, Emmanuelle, et al.. (2001). IFN-β1a May Increase Serum Levels of TIMP-1 in Patients with Relapsing-Remitting Multiple Sclerosis. Journal of Interferon & Cytokine Research. 21(3). 181–185. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact